Fluorination of 3-(3-(piperidin-1-yl)propyl)indoles and 3-(3-(piperazin- 1-yl)propyl)indoles gives selective human 5-HT(1D) receptor ligands with improved pharmacokinetic profiles

Journal of Medicinal Chemistry

Volumn 42, Issue 12, 1999, Pages 2087-2104

  Van Niel, Monique B ^a   Collins, Ian ^a   Beer, Margaret S ^a   Broughton, Howard B ^a   Cheng, Susan K F ^a   Goodacre, Simon C ^a   Heald, Anne ^a   Locker, Karen L ^a   MacLeod, Angus M ^a   Morrison, Denise ^a   Moyes, Christopher R ^a   O'Connor, Desmond ^a   Pike, Andrew ^a   Rowley, Michael ^a   Russell, Michael G N ^a   Sohal, Baibinder ^a   Stanton, Josephine A ^a   Thomas, Steven ^a   Verrier, Hugh ^a   Watt, Alan P ^a   Castro, José L ^a   more..

^a NEUROSCIENCE RESEARCH CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3 [3 (PIPERAZIN 1 YL)PROPYL]INDOLE; 3 [3 (PIPERIDIN 1 YL)PROPYL]INDOLE; ALMOTRIPTAN; ELETRIPTAN; FLUORINE; FROVATRIPTAN; INDOLE DERIVATIVE; NARATRIPTAN; PIPERAZINE DERIVATIVE; PIPERIDINE DERIVATIVE; RIZATRIPTAN; SEROTONIN 1D AGONIST; SEROTONIN 1D RECEPTOR; SUMATRIPTAN; UNCLASSIFIED DRUG; ZOLMITRIPTAN;

ARTICLE; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG SYNTHESIS; FIRST PASS EFFECT; FLUORINATION; INTRAVENOUS DRUG ADMINISTRATION; LIGAND BINDING; MALE; MIGRAINE; NONHUMAN; ORAL DRUG ADMINISTRATION; RAT; RECEPTOR AFFINITY;

ADMINISTRATION, ORAL; ANIMALS; CHO CELLS; CRICETINAE; FLUORINE COMPOUNDS; HUMANS; INDOLES; LIGANDS; MALE; MODELS, MOLECULAR; PIPERIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT1B; RECEPTOR, SEROTONIN, 5-HT1D; RECEPTORS, SEROTONIN; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0033577987     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm981133m     Document Type: Article

References (56)

1. 1 Receptor Agonist, Sumatriptan, for the Acute Treatment of Migraine. Drug Dev. Res. 1992, 26, 235-240.
2. (b) Dechant, K. L.; Clissold, S. P. Sumatriptan: A review of its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Efficacy in the Acute Treatment of Migraine and Cluster Headaches. Drugs 1992, 43, 776-798.
3. (c) Plosker, G. L.; McTavish, D.; Sumatriptan. A Reappraisal of its Pharmacology and Therapeutic Efficacy in the Acute Treatment of Migraine and Cluster Headache. Drugs 1994, 47, 622-651.
4. (d) Perry, C. M.; Markham, A. Sumatriptan: an updated review of its use in migraine. Drugs 1998, 55, 889-922.
5. Silberstein, S. D. Treatment of the migraine attack. Curr. Opin. Neurol. 1994, 7, 258-263.
6. 1D Receptors. J. Med. Chem. 1995, 38, 1799-1810.
7. (b) Cutler, N. R.; Claghorn, J.; Sramek, J. J.; Block, G.; Panebianco, D.; Cheng, H.; Olah, T. V.; Reines, S. A. Pilot Study of MK-462 in Migraine. Cephalagia 1996, 16, 113-116.
8. 1B/D agonists: structure activity relationship and preclinical pharmacological distinctions. Curr. Med. Chem. 1997, 4, 295-312.
9. Ngo, J.; Mealy, N.; Castener, J. Zolmitriptan. Drugs of the Future 1997, 22, 260-269.
10. Gunesekara, N. S.; Wiseman, L. R. Naratriptan. CNS Drugs 1997, 8, 402-408.
11. Ngo, J.; Rabassenda, X.; Castener, J. Eletriptan. Drugs of the Future 1997, 22, 221-224.
12. Meng, C. Q. Migraine: Current Drug Discovery Trend. Curr. Med. Chem. 1997, 4, 385-404.
13. Graul, A.; Leeson, P.; Castener, J. SB-209509/VML-251. Drugs of the Future 1997, 22, 725-728.
14. 1Dβ. Proc. Nat. Acad. Sci. U.S.A. 1992, 89, 3630-3634.
15. 1D receptor subtypes. Trends Pharmacol. Sci. 1996, 17, 103-105.
16. Humphrey, P. P. A.; Goadsby, P. J. The mode of action of Sumatriptan is vascular? A Debate. Cephalagia 1994, 14, 401-410.
17. (a) Buzzi, M. G.; Bonamini, M.; Moskowitz, M. A. The antimigraine drug, Sumatriptan (GR43175), selectively blocks neurogenic plasma extravasation from blood vessels in dura mater. Br. J. Pharmacol. 1990, 99, 202-206.
18. (b) Williamson, D. J.; Shepheard, S. L.; Hill, R. G.; Hargreaves, R. J. The novel antimigraine agent rizatriptan inhibits neurogenic dural vasodilation and extravasation. Eur. J. Pharmacol. 1997, 328, 61-64.
19. 1D Agonist Drugs: Selectively Targetting Additional Sites of Action. Eur. Neurol. 1996, 36, 13-18.
20. (b) Cumberbatch, M. J.; Hill, R. G.; Hargreaves, R. J. Rizatriptan has central antinociceptive effects against durally evoked responses. Eur. J. Pharmacol. 1997, 328, 37-40.
21. 2 Receptors in Serotonin-Induced Contractions of Human Isolated Coronary Arteries. Circulation 1994, 90 (3), 1141-1153.
22. (b) Ferro, A.; Longmore, J.; Hill, R. G.; Brown, M. J. A Comparison of the Contractile Effects of 5-Hydoxytryptamine, Sumatriptan and MK-462 on Human Coronary Artery in vitro. Br. J. Pharmacol. 1995, 40, 245-250.
23. 1D Receptor Agonists and Human Coronary Artery Reactivity in vitro: Crossover Comparisons of 5-HT and Sumatriptan with Rizatriptan and L-741, 519. Br. J. Clin. Pharmacol. 1996, 42, 431-441.
24. 1B receptors, see ref 19.
25. (a) Hillis, W. S.; MacIntyre, P. D. Sumatriptan and chest pain. Lancet 1993, 341, 1564-65.
26. (b) Ottervanger, J. P.; Stricker, B. H. C. Cardiovascular Adverse Reactions to Sumatriptan. Cause for Concern? CNS Drugs 1995, 3, 90-98.
27. (c) Visser, W. H.; Jaspers, N. M. W. H.; de Vriend, R. H. M.; Ferrari, M. D. Chest Symptoms after Sumatriptan: a two-year clinical practice review in 735 consecutive migraine patients. Cephalagia 1996, 16, 554-559.
28. (a) Bouchelet, I.; Cohen, Z.; Case, B.; Seguela, P.; Hamel, E. Differential Expression of Sumatriptan-Sensitive 5-Hydroxytryptamine Receptors in Human Trigeminal Ganglia and Cerebral Blood Vessels. Mol. Pharmacol. 1996, 50, 219-223.
29. 1B-immunoreactivity within the human trigemino-cerebrovascular system: implications for the discovery of new antimigraine drugs. Cephalalgia 1997, 17, 833-841.
30. 1D Receptor Agonists as Potential Antimigraine Agents. J. Med. Chem. 1997, 40, 3501-3503.
31. 1D Receptor Agonists: Fluorinated 3-[3-(Piperidin-1-yl)propyl]indoles. J. Med. Chem. 1998, 41, 2667-2670.
32. (b) Experimental details for the preparation of 7 are included in the Supporting Information.
33. 1B Subtype. J. Med. Chem. 1997, 40, 3497-3500.
34. Welch, J. T.; Eswarakrishnan, S. Fluorine in Bioorganic Chemistry; John Wiley & Sons: New York, 1991; pp 1-6.
35. Hudlicky, M. Fluorination with Diethylaminosulfur Trifluoride and Related Aminofluorosulfuranes. Org. React. 1988, 25, 513-637.
36. 2, 0 °C) from the alcohol: Castro, J. L.; Collins, I. J.; Macleod, A. M.; Moyes, C. R.; Rowley, M.; Showell, G. A. Substituted Piperidine Derivatives as Selective Agonists of 5-HT receptors. WO 9718202 A1 970522, 71 pp.
37. 6-Aza-6-tert-butyloxycarbonyl-1-oxaspiro[2.5]octane (48) was prepared from 1-ter(-butyloxycarbonyl-4-piperidone and trimethylsulfoxonium iodide: Ng, J. S. Epoxide Formation From Aldehydes And Ketones - A Modified Method For Preparing The Corey-Chaykovsky Reagents. Synth. Commun. 1990, 20, 1193-1202.
38. Overman, L. E.; Jacobsen, E. J.; Doedens, R. J. Synthesis Applications of Cationic Aza-Cope Rearrangements. Stereoselective Synthesis of cis- and trans-3a-Aryl-4-oxodecahydrocyclohepta[b]pyrroles. J. Org. Chem. 1983, 48, 3393-3400.
39. Garst, M. E.; Bonfiglio, J. N.; Grudoski, D. A.; Marks, J. Specific Enolates from α-Amino Ketones. J. Org. Chem. 1980, 45, 2307-2315.
40. Lal, G. S. Site-Selective Fluorination of Organic Compounds Using 1-Alkyl-4-fluoro-1,4-diazabicyclo[2.2.21octane Salts (Selectfluor Reagents). J. Org. Chem. 1993, 58, 2791-2796.
41. HH couplings to H-3 anticipated when this proton is axial.
42. Hon, Y.-S.; Lin, S.-W.; Chen, Y.-J. A Convenient And Efficient Workup Of Ozonolysis Reactions Using Triethylamine. Synth. Commun. 1963, 23, 1543-1553.
43. Roberts, J. L.; Borgese, J.; Chan, C.; Keith, D. D.; Wei, C.-C. Synthesis of Potential Transition State Inhibitors of Succinyl C0A: Tetrahydrodipicolinate N-Succinyl-Transferase. Heterocycles 1993, 35, 115-120.
44. Borch, R. F.; Hassid, A. I. A New Method for Methylation of Amines. J. Org. Chem. 1972, 37, 1673-1675.
45. Castro Pineiro, J. L.; MacLeod, A. M.; van Niel, M. B. Preparation of heterocyclyl-substituted azetidine, pyrrolidine and piperidine derivatives as selective agonists of 5-HT1-like receptors. WO 9718201 A1 970522, 57 pp.
46. (a) Hallinan, E. A.; Fried, J. 2,2-difluoro-3-hydroxyesters By Reformatskii Reaction. Tetrahedron Lett. 1984, 25, 2301-2302.
47. (b) Tsukamoto, T.; Yoshiyama, T.; Kitazumi, T. Enantioselective Synthesis of β,β-difluoromalic Acid via Enzymic Resolution of Furyl Substituted Derivative. Tetrahedron Assym. 1991, 2, 759-762.
48. Martin, S. F.; Dean, D. W.; Wagman, A. S. A General Method for the Synthesis of 1,1-difluoroalkylphosphonates. Tetrahedron Lett. 1992, 33, 1839-1842.
49. (a) For a description of this assay, see ref 20.
50. 35S)-GTPγS binding mediated by human muscarinic ml-m4 receptors: Antagonist studies. Br. J. Pharmacol. 1993, 709, 1120-1127.
51. a Determination of Water-Insoluble Substances. Anal. Chem. 1993, 65, 42-49.
52. The structures of N,N′-dimethylpiperazine and N-methyl-4-methyl-4-fluoropiperidine were constructed from the standard fragment library in the Sybyl package (Tripos Inc., St. Louis, Missouri). Optimization was carried out with the AM1 Hamiltonian using the eigenvector following algorithm and precise convergence criteria in MOPAC 6 (Stewart, J. J. P. QCPE #455). Partial charges were calculated for the optimized structures using the ESP method and the electrostatic potential regenerated from these charges classically to produce the contours shown in Figure 1.
53. a relative to N-methylpiperidine is then easily calculated from ΔG= -RT In K. Additionally, the bond orders and localized Orbitals were printed for each of these structures.
54. a relative to N-methylpiperidine is then easily calculated from ΔG= -RT In K. Additionally, the bond orders and localized Orbitals were printed for each of these structures.
55. Lankin, D. C.; Chandrakumar, N. S.; Shashidhar, N. R.; Spangler, D. P.; Snyder, J. P. Protonated 3-Fluoropiperidines: An Unusual Fluoro Directing Effect and a Test for Quantitative Theories of Solvation. J. Am. Chem. Soc. 1993, 115, 3356-3357.
56. The binding mode of 25 and other (2-fluoropropyl)piperazines is likely to be more similar to a recently disclosed series of reversed piperidines than the piperazines based on 3: Ladduwahetty, T. Presented at Trends In Medicinal Chemistry, Society for Medicines Research, December 3, 1998, London, U.K.